Neoleukin Therapeutics, Inc.
NLTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $6,836 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $3,418 |
| Gross Profit | $0 | $0 | $0 | $3,418 |
| % Margin | – | – | – | 50% |
| R&D Expenses | $17,241 | $19,366 | $17,760 | $53,036 |
| G&A Expenses | $6,557 | $6,715 | $8,159 | $10,142 |
| SG&A Expenses | $6,557 | $6,715 | $8,159 | $10,142 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $23,798 | $26,081 | $25,919 | $63,178 |
| Operating Income | -$23,798 | -$26,081 | -$25,919 | -$58,835 |
| % Margin | – | – | – | -860.7% |
| Other Income/Exp. Net | $2,845 | $4,065 | $3,272 | $4,506 |
| Pre-Tax Income | -$20,953 | -$22,016 | -$22,647 | -$54,329 |
| Tax Expense | $0 | $0 | $0 | -$5,905 |
| Net Income | -$20,953 | -$22,016 | -$22,647 | -$48,424 |
| % Margin | – | – | – | -708.4% |
| EPS | -0.99 | -1.05 | -1.08 | 2.41 |
| % Growth | 5.7% | 2.8% | -144.8% | – |
| EPS Diluted | -0.99 | -1.05 | -1.08 | 2.41 |
| Weighted Avg Shares Out | 21,168 | 21,055 | 20,996 | 18,975 |
| Weighted Avg Shares Out Dil | 21,168 | 21,055 | 20,996 | 18,975 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,739 | $2,928 | $3,206 | $5,498 |
| Interest Expense | $1 | $1 | $2 | -$12 |
| Depreciation & Amortization | $776 | $0 | $0 | -$8,203 |
| EBITDA | -$20,176 | -$26,081 | -$25,919 | -$62,544 |
| % Margin | – | – | – | -914.9% |